Top Bioprocessing Companies
Nominate a Company
Usually, the qualified subscribers of our magazine nominate companies with whom they have collaborated and experienced exceptional results to be in this list. Did a company you recently worked with give you stellar results and ROI? Did it turn out to be one you would wholeheartedly recommend to peers? Or do you know of such an outstanding company through your network? Please fill in the details below and nominate them to be featured here.
Top Bioprocessing Companies
Bioprocessing News
Advancing Acute Bleeding Medicine Development through Faster Hemostatic Therapies
Tuesday, September 08, 2026
Fremont, CA: Severe bleeding remains one of the most urgent medical emergencies across hospitals, trauma centers, surgical units and emergency care settings. Every minute matters because rapid blood loss can quickly reduce oxygen delivery to vital organs and increase the risk of long-term complications. Healthcare providers continue to seek treatments that stop bleeding faster while supporting recovery with fewer adverse effects. This growing focus has placed greater emphasis on the development of acute bleeding medicines as researchers and pharmaceutical companies work to improve outcomes through innovative hemostatic therapies. Hemostasis is the body's nat
Choosing an ADC and AOC CDMO Partner for Complex Bioconjugates
Monday, August 24, 2026
Few development decisions carry greater downstream consequences than selecting a CDMO for antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs). Scientific promise alone rarely determines whether a program reaches the clinic on schedule. Process transfer delays, fragmented development ownership and manufacturing approaches that fail to scale often become the larger sources of cost and timeline risk. For emerging biotechnology companies working against limited funding windows, every additional handoff introduces another opportunity for delay. Many organizations still assemble development programs across several specialized providers. One partner may suppo
The State of the Regulatory and Compliance Industry: Business Oversight Takes on a Larger Strategic Role
Thursday, August 20, 2026
Regulatory and compliance programs have become an essential part of modern business management. Organizations face an expanding mix of privacy laws, cybersecurity requirements, financial regulations and industry-specific rules that demand continuous attention. Compliance now supports far more than legal obligations. Strong governance helps businesses protect their reputation, reduce risk and maintain confidence among customers, investors and regulators. Business leaders operate in an environment where regulatory expectations continue to evolve. Financial institutions, healthcare providers, manufacturers and government agencies often manage multiple compliance obligations across
Advancing Targeted Therapies with Next Generation ADC and AOC CDMO Solutions
Wednesday, August 19, 2026
The field of targeted therapy development is evolving rapidly as pharmaceutical and biotechnology companies pursue more precise treatments for complex diseases. Antibody drug conjugates and antibody oligonucleotide conjugates are reshaping the therapeutic landscape by combining selective targeting with advanced payload delivery. This shift has increased the importance of specialized contract development and manufacturing organizations that can support the intricate processes involved in ADC and AOC production. Modern drug developers are seeking partners with deep expertise in bioconjugation chemistry, analytical development process optimization and regulatory support. The comple
Evidence Discipline for Vascular Therapy Decisions
Wednesday, August 12, 2026
Acute myocardial infarction antiplatelet therapy is not a market in which buyers can reward broad vascular claims. A formulary decision touches emergency protocols, discharge planning, bleeding risk, adherence behavior and follow-up across cardiology teams. The gap that matters is often not awareness of antiplatelet science but the discipline to separate drug-grade treatment evidence from adjacent cardiovascular support claims. For executives evaluating products in the longevity and biotechnology market, this distinction protects clinical credibility before price or brand preference enters the room. Procurement pressure tends
Deuterium Drug Discovery needs Chemistry that can Carry Patent Risk
Monday, August 10, 2026
Deuterium chemistry creates an unusual buying problem for pharmaceutical research teams. The science is no longer speculative, yet the specialist base remains thin. A program may begin with a narrow request for a deuterated version of a known molecule, but the commercial question usually sits elsewhere. Which positions can be exchanged, which structures can be protected, which analogs are worth testing and which supplier can make the requested compound without turning the work into a prolonged research detour? That gap matters because deuteration is not simply another intermediate purchase. Specialty chemical buyers can often
